ALPCO to Launch New Zonulin ELISAs and Therapeutic Drug Monitoring Assays for IBD at Digestive Disease Week®
Summary
Included in this launch are two Zonulin ELISAs for the study of gut permeability and celiac disease, as well as therapeutic drug monitoring assays for IBD.When asked why the company chose to launch these products at Digestive Disease Week®, ALPCO President Sean Conley explained, “This meeting hosts physicians, researchers, and academics in the gastroenterology field who, like us, share the common goal of advancing research to help improve patient outcomes.Today, ALPCO offers a wide range of testing solutions, providing scientists and healthcare professionals with vital tools for advancing research and improving quality of care.ALPCO’s therapeutic drug monitoring panel includes ELISAs for testing response to the commonly used biologics adalimumab, infliximab, golimumab, and vedolizumab.Today, ALPCO offers a wide range of testing solutions, providing scientists and healthcare professionals with vital tools for advancing research and improving quality of care.Digestive Disease Week® and DDW® are registered trademarks of the DDW LLC.